United Kingdom

Information for patients and healthcare professionals

The information provided on this page is for general purposes and aims to support the correct and safe use of Farydak® (panobinostat). It is intended to ensure that patients and healthcare professionals are aware of and consider the requirements for the use of Farydak® 10 mg, 15mg and 20mg hard capsules.

Product-related information contained herein is subject to approval by local authorities in the UK.

Reporting of side effects

If you notice any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk

Please, ensure that you provide the brand name, and the specific batch-number.

By reporting side effects, you can help provide more information on the safety of this medicine.

Alternatively, you may report side effects by email to: pv@pharmaand.com

The information you provide will be processed in accordance with the legal requirements. For further information about pharma&’s data handling and privacy policy look at https://www.pharmaand.com/privacy-policy/